Isis Aims High With Lead Diabetes Drug, Still Saddled With Liver Effects
Executive Summary
In Phase II data presented at ADA, glucagon receptor antagonist ISIS-GCGR-Rx works well, but increase in liver enzymes persists as warning sign for the class. Nevertheless, Isis thinks the drug will one day step in when oral drugs start to falter – ahead of injectable GLP-1 agonists.
You may also be interested in...
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.